Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 7Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 199OTHER 167NIH 50NETWORK 18OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Non-squamous Cell Non-Small Cell Lung Cancer 1

Interventions

fludarabine 7Cyclophosphamide 7Nivolumab 6Metformin 4pembrolizumab 3fludarabine phosphate 3Radiotherapy 3Melphalan 3Ipilimumab 3Interleukin-2 3Injections 3S 1 (combination) 2Irinotecan 2tremelimumab 1selinexor 1parsaclisib 1olaparib 1nabiximols 1ivarmacitinib 1durvalumab 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1carfilzomib 1apatorsen 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Topotecan 1Rituximab 1Radiosurgery 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER_GOV × Carboplatin × Clear all
NCT03790228 2020-04-15

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Henan Cancer Hospital

Phase 1 Unknown
43 enrolled
Thoracic

Non-squamous Cell Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡